Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares fell 5.6% during mid-day trading on Wednesday . The stock traded as low as $7.04 and last traded at $7.02. 8,745,283 shares were traded during trading, a decline of 48% from the average session volume of 16,670,846 shares. The stock had previously closed at $7.43.

Analyst Upgrades and Downgrades

RXRX has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -4.74 and a beta of 0.86. The business has a 50 day moving average price of $7.06 and a 200-day moving average price of $6.90.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.43) earnings per share. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Hsbc Holdings PLC grew its holdings in Recursion Pharmaceuticals by 26.0% during the 2nd quarter. Hsbc Holdings PLC now owns 27,972 shares of the company's stock valued at $206,000 after buying an additional 5,764 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Recursion Pharmaceuticals by 32.6% during the second quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company's stock valued at $837,000 after purchasing an additional 27,440 shares during the period. Algert Global LLC bought a new stake in Recursion Pharmaceuticals in the second quarter worth about $129,000. SG Americas Securities LLC raised its holdings in shares of Recursion Pharmaceuticals by 249.0% during the third quarter. SG Americas Securities LLC now owns 89,325 shares of the company's stock valued at $589,000 after acquiring an additional 63,727 shares during the period. Finally, Handelsbanken Fonder AB boosted its stake in shares of Recursion Pharmaceuticals by 33.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company's stock valued at $458,000 after buying an additional 17,400 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.